Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 4
1998 2
1999 2
2000 3
2001 7
2002 2
2003 5
2004 5
2005 5
2006 3
2007 5
2008 6
2009 6
2010 9
2011 8
2012 7
2013 9
2014 5
2015 20
2016 11
2017 7
2018 8
2019 12
2020 7
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 26375942

145 results

Results by year

Filters applied: . Clear all
Page 1
Lack of a significant drug interaction between raltegravir and tenofovir.
Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, Gottesdiener KM, Chen J, Teppler H, Wagner JA, Stone JA, Iwamoto M. Wenning LA, et al. Antimicrob Agents Chemother. 2008 Sep;52(9):3253-8. doi: 10.1128/AAC.00005-08. Epub 2008 Jul 14. Antimicrob Agents Chemother. 2008. PMID: 18625763 Free PMC article. Clinical Trial.
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
Lê MP, Valantin MA, Assoumou L, Soulie C, Le Mestre S, Weiss L, Yazdanpanah Y, Molina JM, Bouchaud O, Raffi F, Reynes J, Calvez V, Marcelin AG, Costagliola D, Katlama C, Peytavin G; ANRS-163 ETRAL study group. Lê MP, et al. Pharmacotherapy. 2019 Apr;39(4):514-520. doi: 10.1002/phar.2242. Epub 2019 Apr 1. Pharmacotherapy. 2019. PMID: 30815916 Free article. Clinical Trial.
Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.
Blonk MI, Colbers AP, Hidalgo-Tenorio C, Kabeya K, Weizsäcker K, Haberl AE, Moltó J, Hawkins DA, van der Ende ME, Gingelmaier A, Taylor GP, Ivanovic J, Giaquinto C, Burger DM; Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women PANNA Network; PANNA Network. Blonk MI, et al. Clin Infect Dis. 2015 Sep 1;61(5):809-16. doi: 10.1093/cid/civ366. Epub 2015 May 5. Clin Infect Dis. 2015. PMID: 25944344 Clinical Trial.
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
Feng HP, Guo Z, Ross LL, Fraser I, Panebianco D, Jumes P, Fandozzi C, Caro L, Talaty J, Ma J, Mangin E, Huang X, Marshall WL, Butterton JR, Iwamoto M, Yeh WW. Feng HP, et al. J Antimicrob Chemother. 2019 Mar 1;74(3):710-717. doi: 10.1093/jac/dky465. J Antimicrob Chemother. 2019. PMID: 30541077 Clinical Trial.
145 results